The NMDA Receptor and Schizophrenia

Abstract

Schizophrenia is a severe mental illness that affects almost 1% of the population worldwide. Even though the etiology of schizophrenia is uncertain, it is believed to be a neurodevelopmental disorder that results from a combination of environmental insults and genetic vulnerabilities. Over the past 20 years, there has been a confluence of evidence from many research disciplines pointing to alterations in excitatory signaling, particularly involving hypofunction of the N-methyl-d-aspartate receptor (NMDAR), as a key contributor to the schizophrenia disease process. This review describes the structure–function relationship of the NMDAR channel and how the glycine modulatory site acts as an important regulator of its activity. In addition, this review highlights the genetic, pharmacologic, and biochemical evidence supporting the hypothesis that NMDAR hypofunction contributes to the pathophysiology of schizophrenia. Finally, this chapter highlights some of the most recent and promising pharmacological strategies that are designed to either, directly or indirectly, augment NMDAR function in an effort to treat the cognitive and negative symptoms of schizophrenia that are not helped by currently available medications.

Introduction

Schizophrenia is a chronic, disabling mental disorder that affects 0.5–1% of the population worldwide (Perala et al., 2007) that commonly presents in late adolescence and early adulthood. It is characterized clinically by positive symptoms (delusions, hallucinations, and thought disorder), negative symptoms (ie, social withdrawal, poverty of speech, and anhedonia), and cognitive deficits (ie, attention, working memory, and executive function). While the negative and positive symptoms typically present during late adolescence or early adulthood (Lewis & Lieberman, 2000), the cognitive deficits generally appear years before clinical diagnosis (Lesh, Niendam, Minzenberg, & Carter, 2011).

One leading hypothesis is that the pathophysiology of schizophrenia has a neurodevelopmental component (Lewis and Lieberman, 2000, Rapoport et al., 2012). Brain development during adolescence, the time when many schizophrenia symptoms appear or worsen, is a dynamic period marked by extensive functional and neuroanatomical changes. This period is characterized by (1) fine-tuning of excitatory, inhibitory, and monoaminergic neurotransmitter systems; (2) stabilization of synapses to increase efficiency of neural function and diminish redundancy; and (3) beginning of integration between late-maturing and early-maturing brain structures (Keshavan, Giedd, Lau, Lewis, & Paus, 2014). Therefore genetic predisposition and environmental disturbances that lead to changes or imbalances in the timing of these developmental processes could increase the risk for developing schizophrenia.

Schizophrenia is associated with various neuroanatomical and structural brain abnormalities. Diffusion tensor magnetic resonance imaging studies show that white matter alterations are present from the preclinical to the chronic stages of schizophrenia, involving the long-association white matter tracts, corticospinal tracts, interhemispheric connections, cerebello-thalamo-cortical circuit, and limbic system (Canu, Agosta, & Filippi, 2015). A number of longitudinal structural magnetic resonance imaging studies have shown reduced whole brain volume and increased lateral ventricular volume in the early stages of schizophrenia and in chronically ill patients (Fusar-Poli et al., 2013, Kempton et al., 2010, Levitt et al., 2010), with some abnormalities already present during the prodromal phase (Fusar-Poli et al., 2011). The decreased brain volume in schizophrenia is especially pronounced in cortical areas, as well as in the hippocampus (Levitt et al., 2010, Tamminga et al., 2010). The extent of progressive brain tissue decrease in patients (− 0.5%/year) has been estimated as twice that of healthy controls (− 0.2%/year) (Hulshoff Pol & Kahn, 2008). Some of these neuroanatomical alterations may be correlated with antipsychotic treatment, as the higher the cumulative exposure to antipsychotic treatment, the greater the progressive gray matter volume decreases in patients over time (Fusar-Poli et al., 2013). Studies using human postmortem brain tissue suggest that decreased neuropil, including reduced dendritic length and spine density on pyramidal neurons, might be the primary contributor to reduced cortical gray matter volumes in schizophrenia (Glausier and Lewis, 2013, Konopaske et al., 2014).

Schizophrenia is a highly heritable disorder, with the relative risk being 6–17 × greater among first-degree relatives and 40–50 × greater in the monozygotic twin of an affected sibling compared to the general population (Cardno et al., 1999). Thus, there has been a massive effort in the field of psychiatric genetics to identify genes that confer risk to developing schizophrenia. Unfortunately, the genetics are very complex with non-Mendelian inheritance. Prior to genome-wide association studies (GWAS), candidate gene studies were utilized in an attempt to discover genetic risk factors for schizophrenia. Although these studies were able to identify numerous risk genes, there was often a failure to replicate associations across studies. We now know that these early candidate gene association studies for common genetic variation had inadequate statistical power to detect the small differences seen in schizophrenia (Farrell et al., 2015). Although the largest schizophrenia GWAS to date (~ 37,000 cases and ~ 113,000 controls; exponentially larger sample sizes than previous studies) identified SNPs in ~ 600 brain-enriched genes, almost all of the previously identified candidate risk genes were not found to be associated with schizophrenia in this study (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). Copy number variants (CNVs) (stretches of DNA that are either deleted or duplicated) and rare exonic variants can also lead to increased genetic risk for schizophrenia (Fromer et al., 2014, Kirov et al., 2012). As a whole, these recent large-scale studies have identified both common and rare genetic variants in N-methyl-d-aspartate receptor (NMDAR) genes, as well as components of the postsynaptic density, with increased risk for schizophrenia.

In this chapter, we describe the structure and function of the NMDAR channel, with a particular focus on how the glycine modulatory site (GMS) regulates its activity. We will then discuss how it is believed that NMDAR hypofunction contributes to the pathophysiology of schizophrenia. Finally, we will highlight some of the latest pharmacological strategies aimed at both, directly and indirectly, augmenting NMDAR function.